We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+17.58%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.97B
AUM Growth
+$703M
Cap. Flow
+$803M
Cap. Flow %
27.04%
Top 10 Hldgs %
34.36%
Holding
350
New
119
Increased
64
Reduced
60
Closed
59

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$25.3M
2
LLY icon
Eli Lilly
LLY
+$24.5M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$18.4M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$15.7M
5
MGNX icon
MacroGenics
MGNX
+$12.2M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$21.4M
2
KALV
KalVista Pharmaceuticals
KALV
+$20.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$17.9M
4
CLDX icon
Celldex Therapeutics
CLDX
+$17.7M
5
PRTA icon
Prothena Corp
PRTA
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 22.28%
2 Consumer Staples 0.05%
3 Financials 0.03%
4 Industrials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
76
PUT
Fate Therapeutics
FATE
$286M
$8.98M 0.3%
108,900
+70,100
+181% +$6.72M
SCPH
77
DELISTED
scPharmaceuticals
SCPH
$8.7M 0.29%
1,308,699
-157,448
-11% -$1.08M
VINC
78
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$8.47M 0.29%
21,934
-5,000
-19% -$2.02M
CMPS
79
Compass Pathways
CMPS
$1.53B
$8.32M 0.28%
225,926
+202,278
+855% +$8.87M
ASND icon
80
Ascendis Pharma A/S
ASND
$16B
$8M 0.27%
62,090
-25,000
-29% -$3.8M
SAGE
81
CALL
DELISTED
Sage Therapeutics
SAGE
$7.8M 0.26%
104,300
+22,600
+28% +$1.85M
LKFT
82
CALL
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$7.71M 0.26%
+100,000
New +$9.21M
EPIX
83
DELISTED
ESSA Pharma
EPIX
$7.69M 0.26%
+264,868
New +$6.16M
SRRA
84
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$7.67M 0.26%
445,188
+126,298
+40% +$2M
NVTA
85
PUT
DELISTED
Invitae Corporation
NVTA
$7.64M 0.26%
+200,000
New +$9.09M
KALV
86
DELISTED
KalVista Pharmaceuticals
KALV
$7.63M 0.26%
296,965
-766,996
-72% -$20.2M
SDGR icon
87
PUT
Schrodinger
SDGR
$1.13B
$7.63M 0.26%
+100,000
New +$8.99M
SRPT icon
88
CALL
Sarepta Therapeutics
SRPT
$1.57B
$7.45M 0.25%
100,000
-401,000
-80% -$37M
ARGX icon
89
CALL
argenx
ARGX
$53.4B
$7.41M 0.25%
+26,900
New +$8.5M
ADCT icon
90
CALL
ADC Therapeutics
ADCT
$134M
$7.32M 0.25%
+300,000
New +$8.69M
MCRB icon
91
Seres Therapeutics
MCRB
$46.8M
$7.21M 0.24%
+17,500
New +$8.06M
AUTL
92
Autolus Therapeutics
AUTL
$397M
$7.2M 0.24%
+1,256,048
New +$9.3M
ITCI
93
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$7.13M 0.24%
210,000
+152,000
+262% +$5.27M
RLMD icon
94
CALL
Relmada Therapeutics
RLMD
$557M
$6.96M 0.23%
+197,600
New +$6.91M
RCUS icon
95
PUT
Arcus Biosciences
RCUS
$3.55B
$6.89M 0.23%
245,500
+225,000
+1,098% +$7.83M
OCUL icon
96
Ocular Therapeutix
OCUL
$1.79B
$6.88M 0.23%
419,573
-265,000
-39% -$5.1M
RVMD icon
97
CALL
Revolution Medicines
RVMD
$39.9B
$6.88M 0.23%
+150,000
New +$6.73M
SAGE
98
DELISTED
Sage Therapeutics
SAGE
$6.82M 0.23%
91,151
+25,000
+38% +$2.05M
ARDX icon
99
Ardelyx
ARDX
$1.22B
$6.82M 0.23%
1,030,436
-125,000
-11% -$858K
VSTM icon
100
Verastem
VSTM
$510M
$6.66M 0.22%
224,533
+36,650
+20% +$1.03M
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Ikarian Capital held 350 positions worth $2.97B, up 31% from $2.27B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Ikarian Capital deployed $803M of net new capital in Q1 2021, opening 119 new positions and adding to 64 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 24% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $21.4M trimmed.

  • Ikarian Capital's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.
  • Ikarian Capital added most to X4 Pharmaceuticals in Q1 2021, an estimated $15.7M increase.
  • Ikarian Capital's biggest Q1 2021 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $21.4M.
  • Ikarian Capital fully exited Bristol-Myers Squibb in Q1 2021, selling an estimated $17.9M.
  • Ikarian Capital's ten largest holdings make up 34% of its $2.97B portfolio in Q1 2021.
  • Ikarian Capital opened 119 new positions and closed 59 in Q1 2021.
  • Ikarian Capital's portfolio value rose 31% quarter-over-quarter to $2.97B.

Based on Ikarian Capital's 13F filing for Q1 2021, filed 17 May 2021.